Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study.
Humans
Lymphoma, B-Cell, Marginal Zone
/ diagnosis
Rituximab
/ adverse effects
Chlorambucil
/ adverse effects
Retrospective Studies
Case-Control Studies
Antibodies, Monoclonal, Murine-Derived
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Treatment Outcome
Translocation, Genetic
MALT
chlorambucil
gastric MALT lymphoma
rituximab
t(11;18) translocation
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
pubmed:
11
6
2022
medline:
15
11
2022
entrez:
10
6
2022
Statut:
ppublish
Résumé
To assess the effectiveness and safety of rituximab alone or in combination with chlorambucil for the treatment of translocation (11;18)-negative gastric MALT lymphoma, we included 71 patients in a retrospective case-control study, 54 treated with rituximab alone and 17 with combination therapy. There was no difference between the groups in complete remission or overall response rates at weeks 25 and 52. After a median follow-up period of 5.8 years (range, 3.3 - 9.7 years), the 5-year progression-free survival probabilities were 60% and 88% in patients treated with rituximab monotherapy and combination therapy, respectively (
Identifiants
pubmed: 35687839
doi: 10.1080/10428194.2022.2086248
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Chlorambucil
18D0SL7309
Antibodies, Monoclonal, Murine-Derived
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM